ClinicalTrials.Veeva
Menu

Find clinical trials for Alzheimer's Disease in Boston, MA

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Alzheimer Disease
Dementia
Cognitive Dysfunction
Mental Disorders
Brain Diseases
Psychomotor Agitation
Nervous System Diseases

Alzheimer's Disease trials near Boston, MA, USA:

A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

designed to evaluate the efficacy, safety, and tolerability of two doses of CT1812 compared to placebo in participants diagnosed with early Alzheimer's...

Enrolling
Early Alzheimer's Disease
Drug: Placebo
Drug: CT1812

Phase 2

Cognition Therapeutics
Cognition Therapeutics

Boston, Massachusetts, United States and 29 other locations

This is a randomized, double-blind, sham-controlled, adaptive-design pivotal study of sensory stimulation in subjects with mild to moderate Alzheimer's...

Enrolling
Alzheimer Disease 6
Dementia of Alzheimer Type
Device: Sensory Stimulation System (GS120) - Sham
Device: Sensory Stimulation System (GS120) - Active
Cognito Therapeutics
Cognito Therapeutics

Boston, Massachusetts, United States of America and 67 other locations

This study is designed to evaluate safety and efficacy of fosgonimeton (ATH-1017) in the treatment of mild to moderate Alzheimer's disease...

Active, not recruiting
Alzheimer Disease
Dementia of Alzheimer Type
Drug: Placebo
Drug: ATH-1017

Phase 2, Phase 3

Athira Pharma
Athira Pharma

Charlestown, Massachusetts, United States and 89 other locations

The reason for this study is to collect safety and efficacy information regarding the study drug remternetug in participants with early Alzheimer's...

Active, not recruiting
Alzheimer's Disease
Drug: Remternetug (SC)
Drug: Placebo

Phase 3

Lilly
Lilly

Watertown, Massachusetts, United States of America and 75 other locations

and pharmacodynamic effects of ACI-24.060 in subjects with prodromal Alzheimer's disease and in non-demented adults with Down syndr...

Enrolling
Prodromal Alzheimer's Disease
Alzheimer's Disease
Biological: Placebo
Biological: ACI-24.060 at Dose D

Phase 1, Phase 2

AC Immune

Boston, Massachusetts, United States and 18 other locations

efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with ...

Enrolling
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Solanezumab
Drug: E2814

Phase 2, Phase 3

The Washington University
The Washington University

Providence, Rhode Island, United States and 37 other locations

To assess the safety, tolerability, biomarker, cognitive, and clinical efficacy of investigational products in participants with an Alzheimer's...

Active, not recruiting
Alzheimers Disease
Alzheimers Disease, Familial
Drug: Lecanemab
Drug: Matching Placebo (E2814)

Phase 2, Phase 3

The Washington University
The Washington University

Providence, Rhode Island, United States and 37 other locations

progression of AD, as compared to no stimulation (OFF), by measuring baseline (pre-implantation) to 12-month change in the integrated Alzheimer's...

Active, not recruiting
Alzheimer Disease
Device: DBS-f On
Device: DBS Off
Functional Neuromodulation

Providence, Rhode Island, United States and 20 other locations

is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Tri...

Enrolling
Preclinical Alzheimer's Disease
Early Preclinical Alzheimer's Disease
Drug: Lecanemab
Drug: Placebo

Phase 3

Eisai
Eisai

Boston, Massachusetts, United States and 117 other locations

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's...

Active, not recruiting
Alzheimer Disease
Drug: LY3372689
Drug: Placebo

Phase 2

Lilly
Lilly

Watertown, Massachusetts, United States of America and 69 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems